NEW YORK, Feb. 22, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on ARGS, ARRY, AUPH, and EARS which can be accessed for free by signing up to www.wallstequities.com/registration. Ahead of today's trading session, WallStEquities.com monitors Argos Therapeutics Inc. (NASDAQ: ARGS),
Shares in Durham, North Carolina headquartered Argos Therapeutics Inc. saw a slight decline of 0.73%, ending Wednesday's trading session at $1.36. The stock recorded a trading volume of 505,961 shares. The Company's shares are trading 47.29% below their 50-day moving average. Moreover, shares of Argos Therapeutics, which focuses on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases, have a Relative Strength Index (RSI) of 29.35.
On February 15th, 2018, Argos Therapeutics announced the issuance of US patent 9,879,053, covering the strain-independent amplification of human immunodeficiency virus (HIV) nucleic acid sequences for use in vaccinations. The methods described in this patent form the foundation for the manufacture of AGS-004, the Company's novel, dendritic cell-based immunotherapy for HIV. Get the full research report on ARGS for free by clicking below at:
Boulder, Colorado headquartered Array BioPharma Inc.'s stock rose 2.73%, closing the day at $17.66 with a total trading volume of 3.22 million shares. The Company's shares have advanced 13.50% in the past month, 53.30% in the previous three months, and 62.32% over the past year. The stock is trading 27.46% and 65.60% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Array BioPharma, which focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and Asia/Pacific, have an RSI of 65.35.
On February 06th, 2018, Array BioPharma reported its results for Q2 FY18. Revenue for the quarter was $42.2 million; cost of partnered programs was $13.7 million; and R&D expense was $42.6 million. Loss from operations for Q2 of fiscal 2018 was $25.7 million, and net loss was $34.1 million. Cash, cash equivalents, and marketable securities as of December 31st, 2017, were $420 million.
On February 07th, 2018, research firm Stifel reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $20 a share to $23 a share. Access the free research report on ARRY now by signing up at:
On Wednesday, shares in Victoria, Canada headquartered Aurinia Pharmaceuticals Inc. recorded a trading volume of 1.11 million shares, which was higher than their three months average volume of 938,830 shares. The stock ended the day 0.55% higher at $5.46. The Company's shares have advanced 6.23% in the previous three months and 48.37% over the past year. The stock is trading above its 50-day moving average by 6.01%. Furthermore, shares of Aurinia Pharma, which engages in the development of a therapeutic drug to treat autoimmune diseases in Canada, have an RSI of 56.50.
On February 08th, 2018, research firm RBC Capital Markets initiated an 'Outperform' rating on the Company's stock, with a target price of $9 per share.
On February 08th, 2018, Aurinia Pharma announced the appointment of Joseph P. "Jay" Hagan to its Board of Directors. Mr. Hagan is currently the President and Chief Executive Officer of Regulus Therapeutics. Are you already registered with Wall St. Equities? Do so now for free, and get the report on AUPH at:
Auris Medical Holding
Zug, Switzerland headquartered Auris Medical Holding AG's stock dropped 1.89%, finishing yesterday's session at $0.26 with a total trading volume of 906,846 shares. The stock is trading below their 50-day moving average by 39.65%. Shares of the Company, which focuses on the development of novel products for the treatment of inner ear disorders, have an RSI of 32.51.
On February 07th, 2018, Auris Medical reported new data on the pharmacokinetics of AM-125, its investigational drug for the intranasal treatment of vertigo. The results show markedly higher blood plasma concentrations when betahistine was administered intranasally rather than orally. In a next step, the Company is planning to test intranasal betahistine in a second phase 1 clinical trial to determine the maximum tolerated dose with single and repeated dosing and to generate additional data on the relative bioavailability compared to oral betahistine. Aspiring Member, please take a moment to register below for your free research report on EARS at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-biotech-stocks----argos-therapeutics-array-biopharma-aurinia-pharma-and-auris-medical-300602599.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!